Express Humanization™
BioAtla’s scientific team has developed a novel approach to rapidly humanize antibodies called Express Humanization™ which is different from and superior to other humanization methodologies.
The technology entails synthesizing a combinatorial library of a non-human target monoclonal antibodies fused in frame to a validated collection of human frameworks. The combinatorial libraries are screened for binding to your antigen of interest. Unlike more traditional approaches such as CDR grafting, this powerful approach allows for the selection of the most favorable combinations of fully human frameworks in terms of expression and maintaining the binding activity to your parental antibody without the need to make back mutations. Historical affinities for BioAtla humanized antibodies range from 0.5X to as much as 5X higher affinity than the starting antibodies’ affinities (see Results/Data below). This rapid and powerful process significantly increases the success rate relative to other technologies. These antibodies are some of the highest quality antibodies for human therapeutics since they are simultaneously selected for expression (see CIAO!™) and other targeted characteristics with an elite set of expressed human frameworks.
RESULTS/DATA:
Rapid Humanization that Retains Affinity
Binding constants of humanized hits:
- Biacore Analysis
- Antibodies coupled to chip
BENEFITS:
Rapid program for generation of superior humanized antibodies
Full length antibodies expressed in mammalian cells
Library of humanized variants:
- High, validated framework diversity – No back-mutations required to retain original affinity – No CDR grafting or phage display required
ELISA based screening (antigen binding) and cell-based screening (biological activity) available
Isotype switch can be included